What Researchers Did
A German committee reviewed the efficacy, appropriateness, and cost-effectiveness of hyperbaric oxygen therapy (HBO) for various indications, including diabetic foot ulcers, to determine reimbursement in ambulatory health care.
What They Found
In 1994, the committee initially declined HBO reimbursement, but initiated a new deliberation in 1999, reviewing over 40 potential indications. For diabetic foot ulcers, they found most clinical trials were retrospective case series, which were deemed insufficient to support HBO as a new therapy.
What This Means for Canadian Patients
Canadian patients with diabetic foot ulcers should be aware that the evidence for hyperbaric oxygen therapy as a standard treatment is not robust. Decisions on new therapies should be based on strong clinical trial data to ensure effective and appropriate care.
Canadian Relevance
This study focuses on health care reimbursement decisions within the German system and has no direct Canadian connection.
Study Limitations
A key limitation was that most clinical trials reviewed for diabetic foot ulcers were retrospective case series, lacking the robust evidence needed for a new technology.